Literature DB >> 16857620

Five cases of bacterial endocarditis after furunculosis and the ongoing saga of community-acquired methicillin-resistant Staphylococcus aureus infections.

Michelle Bahrain1, Minas Vasiliades, Marcos Wolff, Faheem Younus.   

Abstract

Bacterial endocarditis secondary to Panton-Valentine leukocidin producing community-acquired methicillin-resistant Staphylococcus aureus (MRSA) infections is rare. We report 5 previously healthy patients who presented with endocarditis after developing furunculosis due to CA-MRSA. A retrospective chart review of all patients with MRSA positive blood cultures was conducted over a 12-month period. Patients with multiple positive blood cultures within 72 h of admission and who had no risk factors for MRSA acquisition were included. Modified Duke's criteria were used to define bacterial endocarditis. PCR detection of Panton-Valentine leukocidin (PVL) genes as well as SCCmec typing was performed. In addition, strain typing of MRSA isolates was performed utilizing pulsed-field gel electrophoresis. Five out of a total of 193 patients had features consistent with CA-MRSA infections and met modified Duke's criteria for bacterial endocarditis. Blood culture isolates were found to be PVL gene positive and carried the type IV SCCmec element. PFGE confirmed that skin isolate was identical to the isolate cultured from his blood. Bacterial endocarditis in patients with CA-MRSA furunculosis is an emerging entity. In areas where CA-MRSA skin infections are prevalent, inappropriate initial antibiotics remain a major problem and may result in significant morbidity.

Entities:  

Mesh:

Year:  2006        PMID: 16857620     DOI: 10.1080/00365540500447150

Source DB:  PubMed          Journal:  Scand J Infect Dis        ISSN: 0036-5548


  8 in total

1.  Staphylococcus aureus strains isolated from bloodstream infections changed significantly in 2006.

Authors:  Nathalie van der Mee-Marquet; Christophe Epinette; Jeremy Loyau; Laurence Arnault; Anne-Sophie Domelier; Barbara Losfelt; Nicole Girard; Roland Quentin
Journal:  J Clin Microbiol       Date:  2007-01-24       Impact factor: 5.948

Review 2.  Community-associated methicillin-resistant Staphylococcus aureus: epidemiology and clinical consequences of an emerging epidemic.

Authors:  Michael Z David; Robert S Daum
Journal:  Clin Microbiol Rev       Date:  2010-07       Impact factor: 26.132

3.  Methicillin-susceptible, non-multiresistant methicillin-resistant and multiresistant methicillin-resistant Staphylococcus aureus infections: a clinical, epidemiological and microbiological comparative study.

Authors:  W J Munckhof; G R Nimmo; J Carney; J M Schooneveldt; F Huygens; J Inman-Bamber; E Tong; A Morton; P Giffard
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2008-02-16       Impact factor: 3.267

Review 4.  Community-associated meticillin-resistant Staphylococcus aureus infections: epidemiology, recognition and management.

Authors:  Mukesh Patel
Journal:  Drugs       Date:  2009       Impact factor: 9.546

Review 5.  Nasal vestibular furunculosis: Summarised case series.

Authors:  Shirwa Sheik-Ali; Sharaf Sheik-Ali; Azizi Sheik-Ali
Journal:  World J Otorhinolaryngol Head Neck Surg       Date:  2022-05-23

6.  A case of primary infective endocarditis caused by community-associated methicillin-resistant Staphylococcus aureus in a healthy individual and colonization in the family.

Authors:  Seo Young Lee; Jin Yong Kim; Jin Hee Kim; Sue-Yun Kim; Chulmin Park; Yoon Soo Park; Yiel-Hae Seo; Yong Kyun Cho
Journal:  Yonsei Med J       Date:  2009-02-24       Impact factor: 2.759

Review 7.  Recurrent furunculosis - challenges and management: a review.

Authors:  Kristina Sophie Ibler; Charles B Kromann
Journal:  Clin Cosmet Investig Dermatol       Date:  2014-02-18

8.  Severe infective endocarditis with systemic embolism due to community associated methicillin-resistant Staphylococcus aureus ST630.

Authors:  Beiwen Zheng; Saiping Jiang; Zemin Xu; Yonghong Xiao; Lanjuan Li
Journal:  Braz J Infect Dis       Date:  2014-09-01       Impact factor: 3.257

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.